Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

GILEAD COLORADO, INC.

Home Clinical Trial Sponsors and OrganizationsGILEAD COLORADO, INC.

GILEAD COLORADO, INC.

ACTIVE

333 Lakeside Dr, Foster City, California, United Stateswww.myogen.comSubsidiary110 employeesEstablished: 1996-01-01

Part of 吉利德科学

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

2

2 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1996

Overview

Trial Phase Distribution

No trial phase data available

Trial Status Distribution

Active, not recruiting

2

100.0%

Clinical Trials

Trials sponsored by this organization (2)

DORADO-EX ? A Dose-Blinded, Long Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension - DORADO-EX

Active, not recruiting

Jan 2008300 participants

DORADO-Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Four of More Antihypertensive Drugs, Including a Diuretic - DORADO

Active, not recruiting

Jul 2007352 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials2
Approvals
News

Back to Organizations